Friends (19)
June 22, 2015    4 Views    0 Comments
Seventure Partners has added Danilo Casadei Massari and Dr. Thomas Werner to its health for life capital fund investment committee. Massari was a founder and president of CM&D Pharma Ltd, which was sold to Nestle Health Science while Werner is a former managing director at Glaxo SmithKline Germany. PRESS RELEASE
Paris, France –22 June 2015 – Seventure, one of Europe’s leaders in financing innovation, today announced the appointment of Danilo Casadei Massari and Dr Thomas Werner to its Health for Life Capital™ fund Investment Committee. They are two very experienced figures in the international life science sector with outstanding track records which will strengthen Seventure’s team. Danilo Casadei Massari has over 30 years of senior management experience in the pharmaceutical field and is a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical food company sold to Nestle Health Science in 2011. Prior appointments include VP Corporate Development at Madaus Group, CEO of Madaus Italy, and Board positions at Fidia Farmaceutici SpA and Sinclair Pharmaceuticals Ltd. He is currently a Director on the boards of two companies in the US (Prismic Pharmaceuticals Inc and Clinical Information Network Inc) where he is a founding member, and two in Italy (Difass International Srl and InterAlia Srl). Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector. Dr Thomas Werner is an independent highly experienced industry expert for several Venture Capital and Private Equity companies in the healthcare and nutrition sectors. He acts as executive and non-executive member and chairman for numerous boards, including Basilea Pharmaceutica, Riemser Pharma, Skyepharma and BSN medical. He was also involved as Chairman of CM&D Pharma and PharmaSwiss at the time of their exit to Nestle and Valeant. He was also a member of the Board of SuppreMol until their recent acquisition by Baxter. Before then, he was a managing director at Glaxo SmithKline Germany and a Senior Vice President of GSK plc and a managing director at Bristol-Myers Squibb Germany. Isabelle de Cremoux, President and CEO at Seventure Partners, said: “With the recent closing of the Health for Life Capital™ fund, the largest fund worldwide that focusses primarily on microbiome, we are looking for new investment opportunities. Danilo and Thomas’ collective international experience in the pharma, healthcare and nutrition sectors will help considerably in identifying potential new investments and advising us in our strategic approach of this booming field. We welcome them to the team.”
About Health for Life Capital™
In December 2013, Seventure launched Health for Life Capital™, the first venture capital fund focused on investment in the microbiome and nutrition space. Europe is the primary focus of the fund, but it will expand internationally if strategic opportunities arise. The €120m fund attracted strategic investments from prestigious organisations including Danone, Tereos, Tornier and Lesaffre, as well as financial institutions. Health for Life CapitalTM is managed by Seventure’s life sciences team. About Seventure Partners
As one of the leading venture capital firms in Europe, Seventure manages more than €500m. Since 1997, the firm has been investing in innovative businesses with high growth potential, in Digital Technologies in France and Germany, and in Life Sciences across Europe. In Life Sciences, Seventure’s four preferred sectors are:
Microbiome, lifestyle healthcare, personalised medicine and nutrition. Biotechnology and pharmaceuticals
Connected health and medtech
Industrial biotechnology and cleantech
The firm will also look at companies or technologies in diagnostics, biomarkers, drug delivery systems, and services. A typical investment by Seventure ranges from €500k to €10m per round and up to €20m per company, from early to later stage. Seventure is a subsidiary of Natixis, the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more information, please visit: www.seventure.com
Leave a Reply

Seventure beefs up investment committee with two additions

© tmaioliThe beginning of February 2011 was marked with the acquisition of CM&amp;D Pharma, by the Swiss based company nestle. CM&amp;D Pharma was a company that was known to develop and produce patented products for patients with renal disorders. Such an acquisition was made by Nestle through its Health Sciences division. This particular acquisition happens to be the very first deal that came through in just two months since the Health Sciences Division was created. 
 
CM&amp;D, since its inception in 2007, was dedicated to ...

Latest Acquisition In the Pharma Field

Acquired

CM&D was formed with the goal of establishing the first pan-European Specialty Pharma company focused on Foods for Special Medical Purposes (FSMPs). The company has acquired a range of marketed FSMPs and is developing FSMPs to treat a variety of medical conditions. These products benefit from being prescribable in the EU, and yet carry a much lower regulatory burden. This greatly reduces the time to market, regulatory and clinical trial requirements, and therefore the risk of failure to launch.

CM&D Pharma

Nestle

Revance Therapeutics is a privately held specialty biopharmaceutical company which develops next generation products in dermatology and therapeutic medicine. Revance has developed a platform technology, TransMTS that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.

Ajinomoto (TYO: 2802) (MYX: 2658) is a food and chemical corporation that produces seasonings, cooking oils, TV dinners, sweeteners, amino acids, and pharmaceuticals.

Jean Baptiste Agnus

Companies Covered
 Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc.
Key Findings of the Market Report
In 2021, a sizable portion of the distribution channel segment's revenue is anticipated to come from online and retail pharmacies. The dominance is attributable to the rise in retail and online pharmacies in nations like the United States, the United Kingdom, India, and others. A large variety of GLP-2-based pipeline items for short bowel syndrome is the primary reason for the GLP-2 segment's dominance. Hospital pharmacies are anticipated to occupy a sizable portion of the market due to the industry's growing need for cutting-edge medications to treat ailments like Crohn's disease, one of the leading causes of short bowel syndrome. Market Trends for Short Bowel Syndrome
Over the past several years, small bowel syndrome has become more common everywhere. The rise in patients receiving whole parenteral nourishment can be blamed for this. Short bowel syndrome is predicted to have a prevalence of four cases per million and an incidence of three cases per million. The precise incidence of the illness is unknown, and it is assumed based on the number of persons receiving parenteral feeding. The rise in frequency and incidence of uncommon diseases is probably what will drive the global market's expansion. There are now many additional treatments being tested in clinical trials for the management of short bowel syndrome, and there are no approved medications for the illness worldwide. The market's best insights begin with a simple request – get your sample now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346
Short Bowel Syndrome Market Regional Outlook
Various reasons are propelling the growth of the short bowel syndrome market in different regions. These are:
The expansion of the short bowel syndrome market in North America is being driven by the presence of a sizable patient pool embracing cutting-edge medications and needing new treatment alternatives. It is projected that the availability of a broad variety of pipeline items as well as the extended usage of authorized pharmaceuticals to treat adults as well as kids would support market growth in this area over the course of the projection period. Asia Pacific is predicted to have the most rapid CAGR throughout the projection period. The market expansion in this area is fueled by the direct participation of large companies, substantial investments in research and development for the creation of novel pharmaceuticals, and a growing emphasis on GLP-2-based medication clinical trials. Global Short Bowel Syndrome Market: Key Players
Market players for short bowel syndrome are involved in regulatory approvals, the creation of new services, acquisitions, and joint ventures with other businesses. The short bowel syndrome market will probably grow internationally as a result of these tactics over the coming years. The following companies are well-known participants in the global short bowel syndrome market:
Takeda Pharmaceutical Company Limited
2021
The FDA designated Apraglutide, a long-acting GLP-2 analog of the next generation being researched for uncommon gastrointestinal (GI) illnesses, as an orphan drug for the treatment of acute graft-versus-host disease (aGVHD). Receiving an allogeneic hematopoietic stem cell transplant can cause GVHD, a severe, uncommon illness in which the patient's healthy cells are attacked by the donor's immune cells. In the first quarter of 2022, VectivBio AG intends to start a phase 2 study testing Apraglutide for the treatment of aGVHD. Hanmi Pharm. Co. Ltd.
2021
Hanmi Pharm Co. Ltd. disclosed that the United States Food and Drug Administration has given LAPS GLP-2 Analog (HM15912), a treatment for short bowel syndrome, fast-track designation. With the use of the company's platform technology, called Labscovery, a novel biopharmaceutical called LAPS GLP-2 Analog is being created for short-bowel syndrome. The condition has a survival rate of under 50% and impairs children and teenagers' growth adversely. It affects around 24.5 out of every 100,000 infants. For Customization or Any Other Queries, Get in Touch with Our Industry Experts at - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=13346
Global Short Bowel Syndrome Market Segmentation
Product
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports. Contact:

Global Short Bowel Syndrome Market is Anticipated to Reach US$ 3.66 Billion by 2031, Expanding at a Whopping 27% CAGR: TMR Report

Verify here. The information provided by BioPortfolio.com is not a substitute for  professional medical advice, diagnosis or treatment. The BioPortfolio  site is sponsored BioPortfolio Limited with offices at Stafford House,  10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you  are a legal copyright holder or a designated agent for such and you believe a  post on this website falls outside the boundaries of “Fair Use” and  legitimately infringes on your or your client's copyright we may be contacted  concerning copyright matters at: priority@bioportfolio.com. All rights reserved. All other trademarks recognized. Copyright  © 1997-2016 BioPortfolio Limited. Site developed by Alacrify Ltd .

Nutrinia Raises $30M to Continue Development of Specialized Oral Insulin

1 hour 23 min ago
Comments
Nutrinia, a company developing a proprietary oral formulation of insulin for intestinal malabsorption in preterm newborns and Short Bowel Syndrome (SBS) in infants, today announced the closing of a $30 million Series D financing to fund two pivotal trials for registration. TPG Biotech, the life science venture investment arm of leading global alternative asset firm TPG, led the investment, joined by H.I.G. BioHealth Partners and WuXi Healthcare Ventures, as well as existing investors including OrbiMed, Pontifax and others. Nutrinia will use the proceeds to initiate two pivotal trials for registration in separate indications related to acceleration of gut maturation and adaptation: intestinal malabsorption in preterm newborns born between 26 and 32 weeks’ gestational age, and infants with SBS who are under 12 months old. “I’m happy to welcome TPG Biotech, H.I.G. BioHealth Partners and WuXi Healthcare Ventures into Nutrinia at this exciting time for the company,” said Miki Olshansky, Nutrinia’s Chief Executive Officer. “We are beginning two trials in the US and Europe that will provide robust data as to the safety and efficacy of our proprietary oral formulation of insulin, and if successful, provide a direct path to registration. These are orphan indications that affect fragile populations with high levels of unmet medical need.”
“The biological rationale for Nutrinia’s product is strong and the company’s preclinical data and outcomes of multiple previous clinical trials are compelling,” said Eran Nadav, Ph.D., Partner and Managing Director at TPG Biotech. “We believe that neonatology, and specifically the NICU, are areas that deserve particular therapeutic development focus, and we are pleased to support Nutrinia’s efforts.”
With this investment, Dr. Nadav will join Nutrinia’s Board of Directors, as will Aaron Davidson, Co-head and Managing Director of H.I.G. BioHealth Partners.

August 21, 2016 | Israeli biotech startup Nutrinia has closed $30 million Series D financing to fund two pivotal trials for registration. TPG Biotech led the investment, joined by H.I.G. BioHealth Partners and WuXi Healthcare Ventures, as well as existing investors including OrbiMed, Pontifax and others. The Ramat Gan based company is developing a proprietary oral formulation of insulin for intestinal malabsorption in preterm newborns and Short Bowel Syndrome (SBS) in infants. Nutrinia will use the proceeds to initiate two pivotal trials for registration in separate indications related to acceleration of gut maturation and adaptation: intestinal malabsorption in preterm newborns born between 26 and 32 weeks’ gestational age, and infants with SBS who are under 12 months old. Nutrinia was founded by Professor Naim Shehadeh head of Pediatric Diabetes Clinic at the Rambam Medical Center in Haifa, at the NGT incubator in Nazareth, which was supported by the Jacobs family, who invested in the company’s earlier investment round along with Maabarot.

Premature Baby Nutrition Co. Nutrinia Raises $30M

WuXi Healthcare Joins $30M Series D for Nutrinia
8/18/16
RAMAT-GAN, Israel & MORRISTOWN, N.J.--( BUSINESS WIRE )-- Nutrinia, Ltd. , a company developing a proprietary oral formulation of insulin for intestinal malabsorption in preterm newborns and Short Bowel Syndrome (SBS) in infants, today announced the closing of a $30 million Series D financing to fund two pivotal trials for registration. TPG Biotech, the life science venture investment arm of leading global alternative asset firm TPG, led the investment, joined by H.I.G. BioHealth Partners and WuXi Healthcare Ventures, as well as existing investors including OrbiMed, Pontifax and others. Nutrinia will use the proceeds to initiate two pivotal trials for registration in separate indications related to acceleration of gut maturation and adaptation: intestinal malabsorption in preterm newborns born between 26 and 32 weeks’ gestational age, and infants with SBS who are under 12 months old. “I’m happy to welcome TPG Biotech, H.I.G. BioHealth Partners and WuXi Healthcare Ventures into Nutrinia at this exciting time for the company,” said Miki Olshansky, Nutrinia’s Chief Executive Officer. “We are beginning two trials in the US and Europe that will provide robust data as to the safety and efficacy of our proprietary oral formulation of insulin, and if successful, provide a direct path to registration. These are orphan indications that affect fragile populations with high levels of unmet medical need.”
“The biological rationale for Nutrinia’s product is strong and the company’s preclinical data and outcomes of multiple previous clinical trials are compelling,” said Eran Nadav, Ph.D., Partner and Managing Director at TPG Biotech. “We believe that neonatology, and specifically the NICU, are areas that deserve particular therapeutic development focus, and we are pleased to support Nutrinia’s efforts.”
With this investment, Dr. Nadav will join Nutrinia’s Board of Directors, as will Aaron Davidson, Co-head and Managing Director of H.I.G. BioHealth Partners. About Nutrinia, Ltd.
Nutrinia, Ltd. is a clinical stage biotechnology company focused on developing a proprietary oral formulation of insulin for gastrointestinal indications in infants. Insulin has been shown to induce a receptor-mediated response leading to gut maturation and adaptation, important in preterm newborns with intestinal malabsorption and infants similarly affected by Short Bowel Syndrome. There are no approved therapies for either of these orphan conditions. Nutrinia’s unique oral formulation of insulin is locally acting, and stable at room temperature, rapidly dissolving into saline, formula or breast milk, and designed for administration through the plastic tubing used in enteral feeding as well as simply orally. The Company has shown efficacy and safety in animal studies and multiple human clinical trials. Nutrinia is headquartered in Ramat-Gan, Israel, with its US operations based out of Morristown, NJ. For additional information, visit www.nutrinia.com .

WuXi Healthcare Joins $30M Series D for Nutrinia

Applisonix

Evogene

CSG International

Series C

Series D

Nutrinia is a neonatology company focused on developing a proprietary oral formulation of insulin for gastrointestinal indications in infants.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare CM&D Pharma vs Nutrinia

Customers evaluate the quality of CM&D Pharma's products using the following success metrics.